250 related articles for article (PubMed ID: 26830314)
1. Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equation.
Ferreira JA; Peixoto A; Neves M; Gaiteiro C; Reis CA; Assaraf YG; Santos LL
Drug Resist Updat; 2016 Jan; 24():34-54. PubMed ID: 26830314
[TBL] [Abstract][Full Text] [Related]
2. Putative cancer stem cells in malignant pleural mesothelioma show resistance to cisplatin and pemetrexed.
Cortes-Dericks L; Carboni GL; Schmid RA; Karoubi G
Int J Oncol; 2010 Aug; 37(2):437-44. PubMed ID: 20596671
[TBL] [Abstract][Full Text] [Related]
3. Emerging functional markers for cancer stem cell-based therapies: Understanding signaling networks for targeting metastasis.
Marquardt S; Solanki M; Spitschak A; Vera J; Pützer BM
Semin Cancer Biol; 2018 Dec; 53():90-109. PubMed ID: 29966677
[TBL] [Abstract][Full Text] [Related]
4. CD10
Ffrench B; Gasch C; Hokamp K; Spillane C; Blackshields G; Mahgoub TM; Bates M; Kehoe L; Mooney A; Doyle R; Doyle B; O'Donnell D; Gleeson N; Hennessy BT; Stordal B; O'Riain C; Lambkin H; O'Toole S; O'Leary JJ; Gallagher MF
Cell Death Dis; 2017 Oct; 8(10):e3128. PubMed ID: 29048400
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem cells and chemoresistance: The smartest survives the raid.
Zhao J
Pharmacol Ther; 2016 Apr; 160():145-58. PubMed ID: 26899500
[TBL] [Abstract][Full Text] [Related]
6. Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways.
Leon G; MacDonagh L; Finn SP; Cuffe S; Barr MP
Pharmacol Ther; 2016 Feb; 158():71-90. PubMed ID: 26706243
[TBL] [Abstract][Full Text] [Related]
7. Cancer stem-like cells contribute to cisplatin resistance and progression in bladder cancer.
Zhang Y; Wang Z; Yu J; Shi Jz; Wang C; Fu Wh; Chen Zw; Yang J
Cancer Lett; 2012 Sep; 322(1):70-7. PubMed ID: 22343321
[TBL] [Abstract][Full Text] [Related]
8. Cancer Stem Cells and Targeting Strategies.
Barbato L; Bocchetti M; Di Biase A; Regad T
Cells; 2019 Aug; 8(8):. PubMed ID: 31426611
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile.
Latifi A; Abubaker K; Castrechini N; Ward AC; Liongue C; Dobill F; Kumar J; Thompson EW; Quinn MA; Findlay JK; Ahmed N
J Cell Biochem; 2011 Oct; 112(10):2850-64. PubMed ID: 21618587
[TBL] [Abstract][Full Text] [Related]
10. Lung cancer stem cells: The root of resistance.
MacDonagh L; Gray SG; Breen E; Cuffe S; Finn SP; O'Byrne KJ; Barr MP
Cancer Lett; 2016 Mar; 372(2):147-56. PubMed ID: 26797015
[TBL] [Abstract][Full Text] [Related]
11. At the crossroads of cancer stem cells and targeted therapy resistance.
Wang A; Qu L; Wang L
Cancer Lett; 2017 Jan; 385():87-96. PubMed ID: 27816488
[TBL] [Abstract][Full Text] [Related]
12. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
Yan Y; Zuo X; Wei D
Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
[TBL] [Abstract][Full Text] [Related]
13. Markedly increased Oct4 and Nanog expression correlates with cisplatin resistance in oral squamous cell carcinoma.
Tsai LL; Yu CC; Chang YC; Yu CH; Chou MY
J Oral Pathol Med; 2011 Sep; 40(8):621-8. PubMed ID: 21342274
[TBL] [Abstract][Full Text] [Related]
14. RhoGTPases - A novel link between cytoskeleton organization and cisplatin resistance.
Mokady D; Meiri D
Drug Resist Updat; 2015 Mar; 19():22-32. PubMed ID: 25660168
[TBL] [Abstract][Full Text] [Related]
15. Side population cells separated from A549 lung cancer cell line possess cancer stem cell-like properties and inhibition of autophagy potentiates the cytotoxic effect of cisplatin.
Yang Y; Fan Y; Qi Y; Liu D; Wu K; Wen F; Zhao S
Oncol Rep; 2015 Aug; 34(2):929-35. PubMed ID: 26081992
[TBL] [Abstract][Full Text] [Related]
16. Multiple end-point analysis reveals cisplatin damage tolerance to be a chemoresistance mechanism in a NSCLC model: implications for predictive testing.
Almeida GM; Duarte TL; Farmer PB; Steward WP; Jones GD
Int J Cancer; 2008 Apr; 122(8):1810-9. PubMed ID: 18074354
[TBL] [Abstract][Full Text] [Related]
17. Bladder cancer stem cells: biological and therapeutic perspectives.
Goodwin Jinesh G; Willis DL; Kamat AM
Curr Stem Cell Res Ther; 2014 Mar; 9(2):89-101. PubMed ID: 24236543
[TBL] [Abstract][Full Text] [Related]
18. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
Shapira A; Livney YD; Broxterman HJ; Assaraf YG
Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
[TBL] [Abstract][Full Text] [Related]
19. Acquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathway.
Wang H; Zhang G; Zhang H; Zhang F; Zhou B; Ning F; Wang HS; Cai SH; Du J
Eur J Pharmacol; 2014 Jan; 723():156-66. PubMed ID: 24333218
[TBL] [Abstract][Full Text] [Related]
20. Chemical approaches to targeting drug resistance in cancer stem cells.
Sotiropoulou PA; Christodoulou MS; Silvani A; Herold-Mende C; Passarella D
Drug Discov Today; 2014 Oct; 19(10):1547-62. PubMed ID: 24819719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
